The objective is to research, develop and commercialize therapies against “untreatable” cancer targets.

The objective is to research, develop and commercialize therapies against “untreatable” cancer targets.

The objective is to research, develop and commercialize therapies against “untreatable” cancer targets.

AstraZeneca facilities.

AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to research, develop and commercialize targeted therapies against previously difficult-to-target cancer proteins. The Anglo-Swedish company will carry out a initial payment of 66.4 million euros ($75 million).

In addition, Scorpion will be able to receive additional success-based payments in the form of commissions and milestone payments, as well as tiered royalties on net sales in the mid-single to low double digits.

The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes, such as cell growth and survival.

Some transcription factors have long been identified as important targets for developing new cancer treatments and as drivers of disease, but until now they were considered to be could not be addressed by conventional drug discovery methods.

Through this collaboration, Scorpion’s platform will be combined with AstraZeneca’s leadership in the development and commercialization of precision medicines for the treatment of cancer, according to the statement sent by the companies.

Under the terms of the collaboration agreement, Scorpion will lead the discovery and certain preclinical activities. AstraZeneca has the exclusive option to license rights worldwide to up to three drug candidates.

AstraZeneca would be responsible for the activities of development and marketing worldwide upon acceptance, while Scorpion would retain the option to jointly develop and promote up to two of these programs in the United States under certain conditions, even if AstraZeneca exercises three license options.

Adminartua

Leave a Reply

Your email address will not be published.